ホーム › 非小細胞肺癌 › ノースカロライナ › Durham
Durham、NCにおける非小細胞肺癌の臨床試験
Durhamとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する39件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Duke University Medical Center, Durham
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
被験者募集中第2相
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Duke University, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #12, Durham
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
被験者募集中第3相
- UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill · 10マイル先
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
被験者募集中第3相
- Duke Cancer Center, Durham
A Study of PHN-012 in Patients With Advanced Solid Tumors
被験者募集中第1相
- PHN-012-001 Site, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10マイル先
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
被験者募集中第3相
- Duke University Medical Center, Durham
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
被験者募集中第1/2相
- Duke Cancer Center Durham, Durham
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Durham
- Clinical Study Site, Chapel Hill · 10マイル先
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
被験者募集中第3相
- Durham VA Health Care System, Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
被験者募集中第1/2相
- Duke University School of Medicine, Durham
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
被験者募集中第2/3相
- Duke University Medical Center, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
被験者募集中第2相
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · 10マイル先
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- UNC- Chapel Hill, Chapel Hill · 10マイル先
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Duke Cancer Institute, Durham
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 10マイル先
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
被験者募集中第1相
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · 10マイル先
- University of North Carolina, Chapel Hill · 10マイル先
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
被験者募集中第1/2相
- Duke Cancer Institute, Durham
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
被験者募集中第2相
- UNC Health - University of North Carolina, Chapel Hill · 10マイル先
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Duke University Medical Center, Durham
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
被験者募集中第1/2相
- Duke Cancer Institute, Durham
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Duke Cancer Center, Durham
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- Duke Cancer Institute /ID# 276267, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Durham
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
被験者募集中第1相
- Duke Cancer Center /ID# 251975, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Duke Cancer Center, Durham
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Durham VA Medical Center, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
被験者募集中
- Durham VA Medical Center, Durham, NC, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
被験者募集中早期第1相
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- Duke University, Durham
- UNC, Chapel Hill · 10マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chapel Hill · 10マイル先
A Study of NX-1607 in Adults With Advanced Malignancies
被験者募集中第1相
- University of North Carolina, Chapel Hill · 10マイル先
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Durhamにおける他の研究
- 乳がん64件の研究
- がん（全種類）58件の研究
- 多発性骨髄腫37件の研究
- 急性骨髄性白血病33件の研究
- 転移性癌33件の研究
- 前立腺がん32件の研究
- 肺がん32件の研究
- 大腸癌28件の研究
- 卵巣がん27件の研究
- 慢性リンパ性白血病27件の研究
- 心不全26件の研究
- 膵臓がん24件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。